IL42787A - Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids - Google Patents
Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acidsInfo
- Publication number
- IL42787A IL42787A IL42787A IL4278773A IL42787A IL 42787 A IL42787 A IL 42787A IL 42787 A IL42787 A IL 42787A IL 4278773 A IL4278773 A IL 4278773A IL 42787 A IL42787 A IL 42787A
- Authority
- IL
- Israel
- Prior art keywords
- parts
- sodium
- composition
- hydroxy
- calcium salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Indole Compounds (AREA)
Description
Compositions for promotion of protein synthesis and suppression of urea formation 1n the body utilizing analogs of amino The present Invention relates to compositions for promoting protein synthesis and suppressing urea formation 1n the human More the compositions several embodiments of the ment of renal such as for treatment of hepatic such as hyperammonemia and systemic and for alleviating the effects of dietary protein Description of the Prior Prior art treatment of the several bodily disorders to which the present invention finds application varies according to the particular this variation resulting 1n certain instances from a lack of understanding of the metabolic processes Involved in the respective Other than prior art treatments applicable to renal disorders center around replacement of amino acids lacking 1n the individual suffering from said In such a genous wastes resulting from the normal breakdown of amino 1n the body are not adequately excreted and accumulate in the Due to the Inability to excrete these ingestion of elementary protein Reduction of this loss of coupled with conversion of said nitrogenous urea precursors to available amino acids allows bodily conservation of protein without toxic The present compositions generally depend in the several embodiments thereof on the promotion of protein synthesis and suppression of urea formation in the The present invention embodies the now realized need to minimize rather than accelerate the breakdown of urea in the human gut during treatment of renal hepatic and dietary protein The invention particularly comprises a composition of matter including as constituents thereof the analogs of certain essential amino The present composition of matter is generally used in conjunction with attempts to reduce urea breakdown in the body so as to minimize the rate of urea formation by the The present composition of matter generally comprises the analogs of the amino acids listed in the hand column of Table I the column of Table I listing the proper names for the insufficientOCRQuality
Claims (9)
1. A composition for promoting protein synthesis and suppressing urea formation in the body and adapted for oral or parenteral administration to human subjects comprising a mixture of a) the alpha-hydroxy acid analogs of val 1 ne 1 eud ne and Λ Isoleucine or the calcium or sodium salts thereof; b) the hydroxy or keto add analogue of phenylalanine; and c) the amino adds as such of L-tryptophan „ L-threonlne and L-lys1ne or the hydrochloride salt thereof.
2. The composition of claim 1 wherein said analog of phenylalanine 1s present as phenyl pyruvl c add.
3. The composition of Claim 1 further containing L-h1stid1ne.
4. The composition of claim 1 further containing L-arg1n1ne.
5. The composition of claim 1 wherein L-lysine 1s present as the hydrochloride.
6. The composition of claim 1 wherein the hydroxy adds are present therein In the form of the sodium salts.
7. The composition of claim 1 wherein the hydroxy adds are present therein In the form of the calcium salts.
8. A composition adapted for oral or parenteral administration to human subjects 1n the treatment of renal disorders,^ comprising 1n admixture by weight; a) about 1.5 - 2.5 parts phenylpyruvlc add or the sodium or0calc1um salt thereof; b) about 2.0 - 4.0 parts alpha^hydroxylsovalerlc add or the sodium or calcium salt thereof; c) ii^out 3.0 - 5.0 parts alpha-hydroxyisocaprolc acid or the sodl urn or calcium salt thereof; d) about 2.5 - 3.5 parts alpha-hydroxy-beta-methyl valeric acid or the sodium or calcium salt thereof; e) about 1.5 - 2.5 parts al ha-hydroxy-gamma-methyl thlobutyrlc add or the sodium or calcium salt thereof 42787/2 f) about 0.54 parts L-hlstldlne; %) g) about 0.8 parts L-Tys1ne monohydrochlorlde; h) about 0.5 parts L-threonlne; and 1) about 0.25 parts L-tryptophan.
9. A composition adapted for oral or parenteral adjn1n1st-ration to human subjects 1n the treatment of hepatic disorders, comprising n admixture by weight: \ a) about 1.0 - 2.0 parts phenylpyruvlc add or the sodium or calcium salt thereof; b) about 4.0 - 8.0 parts alpha-hydroxylsovaleric acid or the sodium or calcium salt thereof c) about 3.0 - 5.0 parts al ha-hydroxy1socapro1c add or the sodium or calcium salt thereof; d) about 4.0 - 6.0 parts al pha-hydroxy-gamma-methyl thiobutyric acid or the sodium or calcium salt thereof; e) about 0.8 - 1.5 parts alpha-hydroxy-beta-methyl valeric acid or the sodium or calcium salt thereof; f) about 0.1 parts L-tryptophan; g) about 0.4 parts L-threonlne; h) about 0.4 parts L-1ys1ne monohydrochlorlde; and 1) about 1.0 - 4.0 parts L-arginine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35532673A | 1973-04-30 | 1973-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42787A0 IL42787A0 (en) | 1973-10-25 |
| IL42787A true IL42787A (en) | 1977-05-31 |
Family
ID=23397057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42787A IL42787A (en) | 1973-04-30 | 1973-07-19 | Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS49135966A (en) |
| BE (1) | BE803567A (en) |
| CA (1) | CA1023664A (en) |
| DE (1) | DE2335216A1 (en) |
| FR (1) | FR2226994B1 (en) |
| GB (1) | GB1442154A (en) |
| IL (1) | IL42787A (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| DE2530246A1 (en) * | 1975-07-07 | 1977-01-13 | Fresenius Chem Pharm Ind | L-AMINO ACID MIXTURES FOR PARENTERAL OR ORAL USE |
| DE2531299A1 (en) * | 1975-07-12 | 1977-01-13 | Fresenius Chem Pharm Ind | MIXTURES CONTAINING L-AMINO AND HYDROXY AND / OR KETO ACIDS FOR PARENTERAL OR ORAL USE |
| DE2636828A1 (en) * | 1976-08-16 | 1978-02-23 | Fresenius Chem Pharm Ind | (L)-Aminoacid mixt. for treating liver insufficiency - contains isoleucine, leucine, lysine, methionine and cysteine or cystine and non-essential aminoacid(s) |
| US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
| US4752619A (en) * | 1985-12-23 | 1988-06-21 | The Johns Hopkins University | Nutritional supplement for treatment of uremia |
| SE8803143L (en) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | ALTERNATIVE ENERGY SUBSTRATE |
| DE3943424A1 (en) * | 1989-12-30 | 1991-07-04 | Nephro Medica Pharma | Solns. for intravenous nutrition - contg. alpha-keto acids, for patients with kidney conditions, avoids nitrogen cpd. build-up |
| EP2699111A1 (en) * | 2011-04-18 | 2014-02-26 | Nestec S.A. | Nutritional compositions comprising alpha-hydroxyisocaproic acid |
-
1973
- 1973-07-05 GB GB3212173A patent/GB1442154A/en not_active Expired
- 1973-07-11 DE DE19732335216 patent/DE2335216A1/en active Pending
- 1973-07-12 CA CA176,338A patent/CA1023664A/en not_active Expired
- 1973-07-19 IL IL42787A patent/IL42787A/en unknown
- 1973-08-03 FR FR7328498A patent/FR2226994B1/fr not_active Expired
- 1973-08-14 BE BE2052988A patent/BE803567A/en not_active IP Right Cessation
- 1973-10-11 JP JP48114328A patent/JPS49135966A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BE803567A (en) | 1973-12-03 |
| CA1023664A (en) | 1978-01-03 |
| FR2226994B1 (en) | 1977-08-12 |
| DE2335216A1 (en) | 1974-11-21 |
| AU6015373A (en) | 1975-03-13 |
| GB1442154A (en) | 1976-07-07 |
| IL42787A0 (en) | 1973-10-25 |
| FR2226994A1 (en) | 1974-11-22 |
| JPS49135966A (en) | 1974-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4100161A (en) | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids | |
| US4100160A (en) | Therapeutic compositions comprising alpha-hydroxy analogs of essential amino acids and their administration to humans for promotion of protein synthesis and suppression of urea formation | |
| CA2341601C (en) | Use of selenium for treating patients suffering from systemic inflammatory response syndrome (sirs), and composition for implementing said treatment | |
| US5863906A (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| KR840003414A (en) | Pharmaceutical compositions containing 3-hydroxybutanoic acid or salts derived from these acids, and compounds derived from 3-hydroxybutanoic acid that can be used as pharmaceuticals | |
| JPH09512552A (en) | Methods and compositions for treating renal diseases and disorders | |
| EP1696932A1 (en) | Use of treprostinil to improve kidney functions | |
| AU627041B2 (en) | Improved nutritional formulation for the treatment of renal disease | |
| IL42787A (en) | Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids | |
| EP1062879B1 (en) | Aqueous solution for the parenteral nutrition | |
| IL42726A (en) | Composition for promotion of protein synthesis and suppression of urea formation in the body | |
| Connors et al. | The pharmacology and tumour growth inhibitory activity of 1-aminocyclopentane-1-carboxylic acid and related compounds | |
| AU690533B2 (en) | Protein preparation for the prevention and therapy of periodontitis or other bacterial pathologies of the oral cavity | |
| FI88581C (en) | Foerfarande Foer framstaellning av en naeringstillsats Foer behandling av uremi | |
| Gershoff et al. | Effect of vitamin B6 and magnesium on renal deposition of calcium oxalate induced by ethylene glycol administration. | |
| MX2022015524A (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof. | |
| WO2003000173A3 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
| GB1575646A (en) | Therapeutic compositions and their administration | |
| AU2004254154B2 (en) | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition | |
| KR920006904B1 (en) | Pharmaceutical composition containing dimercaptosuccininc acid(dmsa) | |
| US20070141121A1 (en) | Method of treating kidney disease | |
| US20080102042A1 (en) | Oral Composition | |
| JPH0374327A (en) | Excitometabolic agent for alcohol | |
| JPH02131421A (en) | Hepatopathy inhibitor | |
| JP2024008547A (en) | Antibacterial dipeptide compound |